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Abstract. Although yet poorly defined and often misused, the concept of functional mobility has been used in research
studies as a more global and ecological outcome of patients’ health status. Functional mobility is a person’s physiological
ability to move independently and safely in a variety of environments in order to accomplish functional activities or tasks
and to participate in the activities of daily living, at home, work and in the community. Parkinson’s disease (PD) has a direct
impact on patients’ motor control and on mobility in general. Even with optimal medical management, the progression of PD
is associated with mounting impairments at different levels of body function, causing marked limitations in a wide variety of
activities, as well as a severe disability and loss of autonomy. Despite this, for everyday functioning PD patients need to have
a good functional mobility that allow them to get around effortlessly in a reasonable amount of time to access to the same
environments as others. This paper reviewed the concept of functional mobility applied to PD. This was done through an
International Classification of Functioning and Disability (ICF) perspective. Recommendations to address the known factors
that contribute to a poor functional mobility were outlined while suggestions for clinical practice and research were made.
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INTRODUCTION
What is functional mobility? Is there a difference
in the functional mobility of two Parkinson’s disease
(PD) patients with similar gait disturbance, one using
an assistive mobility device, the other not? How do
health professionals account for these differences?
This paper reviewed the functional mobility concept
and its implications for PD patients’ everyday func-
tioning. It followed the International Classification
of Functioning, Disability and Health (ICF) model.
The ICF model goes beyond the usual focus on a
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diagnosis, incorporating detailed information on how
functional, societal aspects, and contextual factors
contribute to a patient’s health condition. Therefore,
it allows to better understand and describe health
and health-related problems and to improve com-
munication between patients, health professionals,
researchers, and policy makers [1, 2]. This model
have been previously used for studying PD patients’
disability [3–5] and quality-of-life [6].
A PubMed search, from inception to June
2017, was made using the following search terms
were: “Functional mobility”, “Mobility”, “Disabil-
ity”, “Participation restrictions” and “Parkinson’s
disease”. Language and publication restrictions were
not applied. Being a narrative review a system-
atic selection of the included studies was also not
ISSN 1877-7171/18/$35.00 © 2018 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
122 R. Bouça-Machado et al. / What is functional mobility applied to Parkinson’s disease?
performed. In order to fully address the opening
question, the concept of functional mobility was
introduced and, through the ICF model, the fac-
tors related with PD body functions impairments
and activity limitations that could affect functional
mobility were presented. It was also discussed how
functional mobility limitation may restrict patients’
everyday functioning and the potential impact of con-
textual factors. Additionally, in the end of the review,
the most suitable outcome tools and interventions
to address PD functional mobility limitations were
appraised.
FUNCTIONAL MOBILITY
Functional mobility is increasingly used as an out-
come in clinical studies as it may provide a more
global and functional perspective of patients’ health
conditions. However, it is still a poorly defined con-
cept, being commonly equated with mobility or
functionality (Fig. 1). According to Forhan & Gill in a
review on obesity [7], functional mobility is the phys-
iological ability of people to move independently and
safely in a variety of environments in order to accom-
plish functional activities or tasks and to participate
in activities of daily living (ADL), at home, work and
in the community. It includes movements like stand-
ing, bending, walking and climbing, which are the
building blocks of ADL, and hence crucial to an indi-
vidual’s independent living and global health status
[7–11]. Impaired functional mobility has been found
to be associated with a greater risk of falls, loss of
independence, and institutionalization [4, 10].
INTERNATIONAL CLASSIFICATION OF
FUNCTIONING AND DISABILITY (ICF)
As formulated by the World Health Organization
(WHO) in 2001, the ICF is conceptualized as a uni-
versal framework focused on the description of how
people live with a health condition (Fig. 2) [4, 7, 12].
Three levels of human functioning are classified:
1) body functions and structures as physiological
and psychological functions, as well as body impair-
ments, and anatomical deficiencies; 2) limitations
in performing tasks or actions; and 3) participation
restrictions in daily-life. Contextual factors can be
either personal, such as age, gender, experiences, and
interests; or environmental like physical, social, and
attitudinal environment. This model assumes that all
levels of human functioning and contextual factors
are interconnected, i.e., impairments in body func-
tions and structures may induce problems in activities
that leads to participation restrictions, which can be
facilitated or hindered by environmental or personal
factors [1, 3].
PARKINSON’S DISEASE
PD is the second most common neurodegenerative
disease [3, 13, 14]. It is characterized by its motor
(bradykinesia, associated with rest tremor and rigid-
ity) and non-motor problems [1, 15, 16].
Despite the variety of therapeutic options, disease
progression usually leads to impairments at different
levels of body function, limitations in a wide
variety of ADL, and in severe disability, social
Fig. 1. Functional mobility concept.
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Fig. 2. ICF framework. Adapted from World Health Organization (2002) [12].
embarrassment and increasing dependence. Gradu-
ally, it reduces health-related quality of life (HrQoL)
and increases the burden of patients and caregivers
[3, 5, 17, 18].
FUNCTIONAL MOBILITY IN PD:
ICF-BASED METHODOLOGY
In order to improve patients’ global health status
and reduce disease burden associated with func-
tional immobility, it is important to understand
a patient’s personal needs, activity and environ-
ment [4]. In this section, we present the three levels
of human functioning included in the ICF frame-
work: 1) the impairments to body structures and
functions relevant to PD patients’ functional mobil-
ity; 2) how the activities that compose functional
mobility are compromised by these impairments, in
a functional perspective; 3) participation restrictions
that PD patients may encountered, induced by func-
tional mobility limitations; 4) lastly, some examples
of frequent personal and environmental factors that
influence the first three domains are presented (Figs. 3
and 4).
Body functions and structures domain
Functional mobility requires dynamic neural con-
trol to quickly and effectively adapt locomotion,
balance, and postural transitions to changing envi-
ronmental and task conditions. This in turn requires
sensorimotor agility that involves: 1) coordination
of complex sequences of movements, 2) on-going
evaluation of environmental cues and contexts, 3)
the ability to quickly switch motor programs with
environmental changes, and 4) the ability to maintain
safe mobility during multiple motor and cognitive
tasks [7, 11].
Motor symptoms
Motor symptoms may contribute to functional
mobility impairments directly, through gait impair-
ments cause by non-dopaminergic pathways degener-
ation and indirectly due to bradykinesia and rigidity,
which affect PD patients gait, balance and transitions
[14, 19–21]. Gait impairments are complex to char-
acterize because of the difficulty in distinguishing
between the specific contribution of sensory, motor,
and cognitive deficits and other factors like fear,
muscle weakness or misjudgement of hazard risk.
Evidence suggests that in later stage cholinergic dys-
function in the pedunculopontine nucleus has a key
role in gait disturbance [14].
With disease progression, severe and disabling
postural deformities are usually present (e.g., camp-
tocormia, antecollis, pisa syndrome or scoliosis).
These interfere with daily living activities, often lead-
ing to falls. Although still not well understood, a
series of central and peripheral causes have been
proposed to explain the complex and multifaceted
underlying pathophysiology of these deformities
[14, 22].
Non-motor symptoms
Functional mobility is also affected by PD non-
motor symptoms.
The inability to simultaneously carry out a cog-
nitive and a motor task is a predictor of falls and
a critical element to functional mobility. This has
been found to be more difficult for PD patients than
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Fig. 3. The concept of functional mobility applied to PD in an ICF perspective.
Fig. 4. Human domains and contextual factors contribution to PD functional mobility.
healthy controls, especially when walking is one of
the tasks [11].
Dysautonomia seems also to play an impor-
tant role in PD functional mobility. In concrete,
orthostatic hypotension symptoms are a frequent
complaint, associated to a higher prevalence of falls
and a more rapid PD progression. It also affects
mobility in general, patients’ confidence in their
own abilities and may undermine an active style
of life [23].
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Additionally, patients have frequently fatigue
complaints, which has physical and psychological
repercussions in PD functional mobility. The feel-
ing of being tired all day and of not knowing how
to get through the day makes fatigue, in patients per-
spective one of the symptoms most difficult to cope
with [14, 24].
Activity domain
In PD, activity limitations range from minor
difficulties (e.g., fine motor coordination tasks) to
more serious problems (e.g., skilled ADL motor
tasks). Patients generally experience a loss of func-
tional mobility resulting from the neurodegenerative
effects of the disease in posture, balance, postural
stability, and gait. Loss of independence in per-
forming activities arises in the transition between
Hoehn and Yahr (H&Y) stages III and IV, and
activities such as walking, housework, dressing
and transfers are the most affected [1, 5, 7, 9,
13, 25, 26].
Walking
Patients describe gait disorders as a loss of confi-
dence in walking, a feeling of imbalance or reduced
ability to negotiate uneven terrain or stairs. A slower
walking speed is often the first noticeable sign of
parkinsonism [19].
Gait is defined as the forward propulsion of the
body with rhythmical coordination of all four limbs
combined with control of dynamic equilibrium of
the body’s center of mass. It is also a complex
sensorimotor activity that involves spatial-temporal
coordination of the legs, trunk and arms, as well as
dynamic equilibrium.
Gait of PD patients have been shown to be: 1) sig-
nificantly slower (typically 40–60 m/min rather than
75–90/min in age-matched controls), 2) with less
foot clearance (foot’s height during the swing phase)
and an increased double phase support in the gait
cycle (from the usual 20–30% of the gait cycle to
over 35%), 3) with smaller step lengths (0.4–0.9 m
for PD patients after withdrawal of medication or
0.8–1.0 m for those at the end-of-dose compared with
1.2–1.5 m for healthy older people), 4) narrow based,
5) asymmetrically reduced or absent arm swing 6) and
stooped posture. Small shuffling steps (resulting from
the reduced ground clearance and increased double
phase support in gait cycle), a bilaterally reduced arm
swing and slow, en bloc turns are also common [1,
14, 27, 28].
Walking problems are usually more pronounced
during gait initiation, turning, walking through door-
ways and when performing simultaneous motor or
cognitive tasks. These relates with the triggering of
festination and freezing episodes, characterize by the
sudden inability to generate effective stepping move-
ments [28]. During festination episodes, the feet are
behind the center of gravity, which causes rapid small
steps. Freezing episodes are described by patients as
having the feet “glued to the floor”, which usually
does not present as complete akinesia, but rather as
shuffling with small steps or trembling of the legs.
Transitions
Throughout the course of disease, transitions
become truly affected and predict risk of falls. Are
particularly problematic: rising from, and sitting
down on a chair, getting in or out and turning over in
bed [1, 27]. Sitting-to-standing is a complex compo-
nent of some everyday functional tasks that requires
the body to accelerate forward and then upward,
and to transfer from a large to a small base of
support to achieve an uprightb stance [1, 29]. PD
patients exhibit a general slowness when compared
to control subjects in performing this tasks with a
spatiotemporal pattern preserved [30]. This indicates
that PD patients’ problems are not related with the
selection, but in initiating and sequencing the appro-
priate motor program. Additionally, task analysis has
shown that PD patients take a significantly longer
time to complete each individual phase and a have
a significantly smaller peak hip extension and ankle
dorsiflexion torque when compared with control sub-
jects [29]. The likely responsible factors are weak
limb support against gravity (particularly reduced
muscle power of the hip extensors), the difficulty
in muscle activation and the inability to counteract
unexpected external forces, vestibular impairment,
and orthostatic hypotension [1, 29, 31]. PD patients
seem also to have less body position changes during
the night compared to the general population, which
may affect sleep quality. Impaired bed mobility is
often attributed to nocturnal hypokinesia, yet pain and
overall muscle weakness and external factors such as
bedcovers or reduced levels of levodopa at night, may
also contribute to difficulty turning over in bed. The
precise causal mechanism is still not clear [1, 32].
Participation domain
Participation problems are aspects of life as a mem-
ber of society hindered by activity limitations [11].
Impairments in PD patients’ functional mobility, may
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compromise involvement in leisure, work or social
aspects of life in both household and community
settings.
Working capacity, often affected in PD patients,
is a concrete example of an important participation
restriction related with functional mobility, not only
because of work role in active fighting against exclu-
sion from social and occupational environments, but
also as livelihood [7, 33].
Contextual factors
Contextual factor could be personal or environ-
mental, and have a positive or negative effect.
Age, a high body mass index, feeling disabled and
social embarrassed represent some examples of per-
sonal factors with potential negative influence on PD
patients’ functional mobility. In contrast, high edu-
cation levels and sport habits are examples of factors
with a positive influence [1, 7, 18].
Similarly, unemployment, loneliness and the
inability to drive, are examples of possible envi-
ronmental negative factors. The existence of family
caregivers is the most valued environmental positive
factor, once PD patients rely on them for most of their
ADL needs [1, 7, 18].
Within personal factors, perceived control (i.e.,
the person’s belief of controlling the situations and
act in accordance to that) is a prime candidate and
a powerful predictor of active life and functional
mobility [26]. PD clearly affects patients’ perceived
control, not only because of the impact of motor and
non-motor symptoms on daily functional mobility,
but also because of the unpredictability and social
embarrassment frequently associated. This has mul-
tiple manifestations in patients’ life, such as: to avoid
walking on the street or in less familiar places due
to fear of falling, concerns scheduling appointments
because of not being sure of being able to get through
it or to stay away from public places or social events to
prevent feeling embarrassed with disease limitations
[2, 16, 19, 26, 34, 35].
FUNCTIONAL MOBILITY: SCALES AND
TOOLS AVAILABLE
Functional mobility is a global disease-related fea-
ture that may provide adequate information about
treatment responses and disease course, as it may
encompasses one of the outcomes most relevant to
patients’ daily lives [9].
Due to the heterogeneity and complexity of PD,
its fluctuating nature and unpredictable medica-
tion response in advanced disease stages, clinical
assessment is challenging and requires continuous
prolonged periods of evaluation to reach an accurate
picture of symptoms and their fluctuations [36].
The majority of PD studies that have mea-
sured functional mobility used rating scales like
the MDS-UPDRS, infrequent events (e.g., falls) or
subjective reports (e.g., diaries or questionnaires).
Objective assessments, including the five-time sit-to-
stand (FTSTS) test and the timed up-and-go (TUG)
test, are two of the most commonly used tools [10,
37, 38]. In 2015, Parashos and colleagues validated
the “Ambulatory Capacity Measure”. This is a mea-
sure of functional capacity, previous used in clinical
trials, derived from UPDRS items related to falls,
freezing, walking, gait and postural instability. It
showed to be a good instrument, highly correlated
with some of the most used outcome tool to assess
functional capacity [39]. However, there is still no
consensus about which screening tools are preferred
or which outcomes are most suitable for monitoring
functional mobility [40].
With technological advances, numerous devices
have been created not only with the capacity of
reliably evaluating fluctuating or rare events (e.g.,
freezing of gait or falls) that usually occur out-
side clinical visits, but also for obtaining more
global, objective, and sensible outcomes for assess-
ing patients’ performance in ADL [41]. Yet, is still
lacking to establish a specific protocol or metrics to




Due to PD heterogeneity, patients’ experience of
mobility impairment and respective coping strategies
are very personal. In order to find an effective option
is crucial to understand the patients’ needs and offer
suggestions according to local offerings, personal
preferences, and cultural background [9, 11].
Exercise programs
Evidence shows that critical aspects of PD patients’
functional mobility impairments (e.g., postural insta-
bility) are unresponsive to pharmacological and
surgical therapies, making physical therapy an attrac-
tive option [9, 11].
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Previous animal studies have demonstrated that
intense exercise programs can increase dopamine
synthesis and release and improve brain func-
tion. Aerobic exercise (e.g., treadmill training) has
shown to improve gait parameters, quality of life,
and levodopa efficacy in PD patients. However,
once functional mobility also depends on other
components such as dynamic balance, dual task-
ing, and other sensorimotor skills, aerobic training
is not sufficient to improve functional mobil-
ity in PD [11]. Task-specific exercises targeting
a single, specific balance or gait impairment, in
PD patients have also been tested with positive
results [9].
Rehabilitation programs have been reported to be
effective in preventing and improving PD patients’
functional mobility when focusing on aerobic exer-
cises and self-initiated movements, big and quick
movements, large and flexible centers of mass con-
trol, reciprocal and coordinated movements of arms
and legs, and rotational movements of torso over
pelvis and pelvis over legs [11].
Strategy training
Strategy training is one of the key elements of phys-
iotherapy PD management. It is defined as teaching
the person how to move more easily and to main-
tain postural stability by using cognitive strategies.
This includes two different methods: acquiring new
motor skills (learning strategies) and compensating
for movement disorders by bypassing the defective
basal ganglia (compensating strategies) [42].
There is growing evidence that, at least in early PD,
the capacity to learn new motor skills is not affected
[42]. One study showed that PD patients with mean
disease duration of 7 years have the capacity to learn
new upper-limb movement sequences, improve per-
formance and retain it for 48 hours [42, 43]. Another
study evaluated a multiple-task gait-training program
in mild PD patients (H&Y stages II–III), reporting
that study participants could maintain their learned
increased multiple-task walking speed over 3 weeks
[42, 44].
Compensatory strategies have been shown to be
effective in moderate to severe PD patients, however
requiring high mental effort and with relatively short-
term effects. They include: the use of visual (e.g.,
white lines on the floor) and auditory (e.g., rhyth-
mical beat provided by a metronome) external cues,
the visualization of walking with long steps, men-
tal rehearsal of the desired movement pattern before
performing the action and breaking down long or
complex motor sequences into parts and focusing on
the performance of each individual segment (segmen-
tation).
Through the mechanism of consciously thinking
about the desired movement, using the frontal cor-
tex to regulate movement size or timing instead of
the defective basal ganglia, PD patients arguably
compensate for the neurotransmitter imbalance in
the basal ganglia obtaining a more normal gait pat-
tern [42]. The type of strategy, the frequency and
duration of training should be considered according
to disease severity, the capacity to learn, and whether
there are coexisting conditions that limit the ability
to practice (Table 1) [42].
Assistive mobility devices
PD patients with functional mobility impairments
need to be able to move effortlessly, in a reasonable
Table 1
Strategies training guide adapted from Morris et al. (2010) [42]
Training strategy: learning strategies to improve
performance through practice
Program:
Mild to moderate disease – 3 times/week
– Peroids of 6 to 8 weeks (motor skill acquisition)
– Burst of therapy 2 to 3 times/year (to promote
retention of training)
Severe disease
Training strategy: compensatory strategies to
by-padd the defective basal ganglia
Cognitive impairments Use: External cues, reminders and segmentation of
action into simple componentsCompromised skill acquisition
Multi-tasking activities: use as training strategy,
educate the patients on its risks
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amount of time throughout their day, accessing the
same environments as others [45].
The use of assistive mobility devices (e.g.,
wheelchairs, walker) increases the ability of individ-
uals to work, perform self-care, and engage in leisure
and social activities independently, enhancing their
functional performance, autonomy and participation
[45–47].
Despite the potential advantages of assistive mobil-
ity devices, they are often underused or abandoned.
The reason relates to a mismatch between a patient’s
functional needs, preferences and environmental con-
strains, and health professionals’ perspectives. In
2017, Bettecken et al. [48] reported a relationship
between PD patients’ gait velocity using an assis-
tive mobile device and their HrQoL. Surprisingly,
the study did not show a relevant contribution of
gait velocity to HrQoL. Also, a relevant portion of
PD patients with high HrQoL preferred a low self-
preferred gait velocity to the use of an assistive mobile
device. In a study to identify clinicians’, patients’
and caregivers’ perspectives about relevant param-
eters and assessment tools for PD symptoms [49],
Ferreira and colleagues reported that patients and
caregivers have different perspectives when select-
ing the most relevant parameters for evaluating gait
and sway domains. Patients and caregivers both high-
lighted the capability of performing ADL as the
most important parameter. For clinicians, time con-




If PD patients are unable to move at an intensity
and frequency that life requires, they may become
excluded from social and occupational environments,
which may negative impacts theirs global health
status [7, 29].
Although the assessment of specific outcomes, like
level of rigidity or intensity of tremor, is important,
previous studies have shown that functional limi-
tations, rather than physical impairments, were the
most problematic aspect of a PD patient’s disabil-
ity profile [5, 7]. The standard scale for evaluating
impairments in PD is the MDS-UPDRS. However,
besides being highly time-consuming, the objective
evaluation of functional activities is limited. The
TUG test is the most used tool to classify functional
mobility and has been shown to be a valid predictor
of performance in ADL. Yet, an exhaustive mea-
surement system that adequately assesses functional
mobility is still needed [3, 7, 8].
More studies are needed to understand the relation-
ship between the use of assistive mobility devices,
PD patients’ functional mobility and HrQoL. Per-
ceived control may be the key aspect in explaining the
intriguing conclusion that Bettecken and colleagues
found in their study [48]. As mentioned above, per-
ceived control is a powerful predictor of functioning
and it seems that some patients place more value
on the capability of performing ADL rather than
the time it takes to perform specific tasks [26, 49].
We hypothesize that assistive mobility devices are
acknowledge by patients as an effective solution only
when perceived as a control gain. Otherwise, the use
of assistive mobility devices is seen as a loss of auton-
omy with negative impact in HrQoL (even objectively
improving gait characteristics such as velocity). It
would also be interesting and useful to study if, for
those PD patients who remain in employment, or
who maintain an active social life, this hypothesis
is valid.
CONCLUSION
Back to our initial question: is there a difference in
the functional mobility of two PD patients with sim-
ilar gait disturbance, one using an assistive mobility
device, the other not? How do health professionals
account for these differences?
This question can be seen from two different per-
spectives.
As a physiological ability, the two patients have
the same degree of functional mobility, since what
differentiated them was the use of an external device.
As an outcome measure eligible to be improved
by a therapeutic intervention, the answer is not so
clear. On one hand, assistive mobility devices enable
a more active and safer lifestyle, allowing patients to
continue to be engaged with their social and occu-
pational environment. For this reason, the patient
with an assistive mobility device has better functional
mobility. On the other hand, this would only be true if
the use of these devices increases patients’ perceived
control of their situation.
Understanding the determinants of functional
mobility in individuals with PD, such as the prece-
dence of perceived control over an improved gait
velocity, will help clinicians to more easily select the
most appropriate therapeutic interventions based on
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an accurate, global, and personalized evaluation of
patients’ problems [7, 27, 31].
From this review on PD patients functional mobil-
ity, we highlight: 1) its benefits as a more global
and functional outcome of patient assessment; 2)
the important role of exercise programs, training
strategies and assistive devices in improving patients’
functionality and participation in social environ-
ments; and lastly, 3) the importance of taking into
account patients’ personal needs and wishes and
environmental factors in order to optimize treatment
strategies.
ACKNOWLEDGMENTS
No specific funding was received for this work.
CONFLICTS OF INTEREST
The authors have no conflict of interest to report.
REFERENCES
[1] Keus S, Munneke M, Graziano M, Paltamaa J, Pelosin
E, Domingos J, Bruhlmann S, Ramaswamy B, Prins J,
Struiksma C, Rochester L, Nieuwboer A, & Bloem B, on
behalf of the Guideline Development Group (2014) Euro-
pean Physiotherapy Guideline for Parkinson’s Disease, 1st
ed. The Netherlands.
[2] Lomax CL, Brown RG, & Howard RJ (2004) Measuring dis-
ability in patients with neurodegenerative disease using the
“Yesterday Interview.” Int J Geriatr Psychiatry, 19, 1058-
1064.
[3] Raggi A, Leonardi M, Ajovalasit D, Carella F, Soliveri P,
Albanese A, & Romito L (2011) Disability and profiles of
functioning of patients with Parkinson’s disease described
with ICF classification. Int J Rehabil Res, 34, 141-150.
[4] Leonardi M, Meucci P, Ajovalasit D, Albanesi F, Cerni-
auskaite M, Invernizzi V, Lembo R, Quintas R, Sattin D,
Carella F, Romito L, Soliveri P, Bussone G, D’amico D,
Maggi L, Mantegazza R, & Raggi A (2009) ICF in neurol-
ogy: Functioning and disability in patients with migraine,
myasthenia gravis and Parkinson’s disease. Disabil Rehabil,
31, S88-S99.
[5] Leonardi M, Raggi A, Ajovalasit D, Bussone G, & D’Amico
D (2010) Functioning and disability in Parkinson’s disease.
Disabil Rehabil, 32(Suppl 1), S23-S32.
[6] van Uem JMT, Marinus J, Canning C, van Lummel R, Dodel
R, Liepelt-Scarfone I, Berg D, Morris ME, & Maetzler
W (2016) Health-Related Quality of Life in patients with
Parkinson’s disease-A systematic review based on the ICF
model. Neurosci Biobehav Rev, 61, 26-34.
[7] Forhan M, & Gill SV (2013) Obesity, functional mobility
and quality of life. Best Pract Res Clin Endocrinol Metab,
27, 129-137.
[8] Swarowsky A, Santos MP, Silva BA, Ovando AC, & Ilha J
(2016) Comparison between two functional mobility scales
for Parkinson’s disease directly applied to physical therapy
practice: Cross-cultural adaptation and measurement prop-
erties. Eur J Phys Rehabil Med, in press.
[9] Burgess S, & Rassmusson X (2016) Parkinson’s narratives:
Onset experiences and perceived benefits of preferred phys-
ical activity. Adv Soc Sci Res J, 3, 150-160.
[10] Lin SI, Lee HC, Chang KC, Yang YC, & Tsauo JY (2017)
Functional mobility and its contributing factors for older
adults in different cities in Taiwan. J Formos Med Assoc,
116, 72-79.
[11] King LA, & Horak FB (2009) Delaying mobility disabil-
ity in people with Parkinson disease using a sensorimotor
agility exercise program. Phys Ther, 89, 384-393.
[12] World Health Organization (2002) Towards a common
language for functioning, disability and health: The Interna-
tional Classification of Functioning, Disability and Health.
Int Classif, 1149, 1-22.
[13] Duncan RP, & Earhart GM (2014) Are the effects of
community-based dance on Parkinson disease severity, bal-
ance, and functional mobility reduced with time? A 2-year
prospective pilot study. J Altern Complement Med, 20, 757-
763.
[14] Magrinelli F, Picelli A, Tocco P, Federico A, Roncari L,
Smania N, Zanette G, & Tamburin S (2016) Pathophysi-
ology of motor dysfunction in Parkinson’s disease as the
rationale for drug treatment and rehabilitation. Parkinsons
Dis, 2016, 1-18.
[15] Kalia LV, & Lang AE (2015) Parkinson’s disease. Lancet,
6736, 1-17.
[16] Sveinbjornsdottir S (2016) The clinical symptoms of
Parkinson’s disease. J Neurochem, 139, 318-324.
[17] Raggi A, Leonardi M, Covelli V, Sattin D, Scaratti C, Schi-
avolin S, Willems M, & Meucci P (2015) The ICF as a
framework to collect and interpret data on the extent and
variety of disability in neurological conditions. NeuroRe-
habilitation, 36, 17-22.
[18] Raggi A, Covelli V, Leonardi M, Meucci P, Scaratti C, Schi-
avolin S, Willems M, & Sattin D (2015) Determinants of
disability using count-based approaches to ICF-based def-
inition of neurological disability. NeuroRehabilitation, 36,
23-29.
[19] Williams DR, & Litvan I (2013) Parkinsonian syndromes.
Contin Lifelong Learn Neurol, 19, 1189-1212.
[20] Postuma RB, Berg D, Stern M, Poewe W, Olanow CW,
Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday
G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler
CH, & Deuschl G (2015) MDS clinical diagnostic criteria
for Parkinson’s disease. Mov Disord, 30, 1591-1601.
[21] Robichaud JA, & Corcos DM (2005) Motor deficits, exer-
cise, and Parkinson’s disease, Quest, 57, 79-101.
[22] Yoshii F, Moriya Y, Ohnuki T, Ryo M, & Takahashi W
(2016) Postural deformities in Parkinson’s disease -Mutual
relationships among neck flexion, fore-bent, knee-bent and
lateral-bent angles and correlations with clinical predictors.
J Clin Mov Disord, 3, 1.
[23] Merola A, Romagnolo A, Rosso M, Lopez-Castellanos JR,
Wissel BD, Larkin S, Bernardini A, Zibetti M, Maule S,
Lopiano L, & Espay AJ (2016) Orthostatic hypotension
in Parkinson’s disease: Does it matter if asymptomatic?
Parkinsonism Relat Disord, 33, 65-71.
[24] Boersma I, Jones J, Carter J, Bekelman D, & Miyasaki JM
(2016) Parkinson disease patient’s perspectives on palliative
care needs What are they telling us? Neurol Clin Pract, 6,
209-219.
[25] Schilling BK, Karlage RE, LeDoux MS, Pfeiffer RF, Weiss
LW, & Falvo MJ (2009) Impaired leg extensor strength in
130 R. Bouça-Machado et al. / What is functional mobility applied to Parkinson’s disease?
individuals with Parkinson disease and relatedness to func-
tional mobility. Park Relat Disord, 15, 776-780.
[26] McQuillen AD, Licht MH, & Licht BG (2003) Contri-
butions of disease severity and perceptions of primary
and secondary control to the prediction of psychoso-
cial adjustment to Parkinson’s disease, Heal Psychol, 22,
504-512.
[27] Horak FB (2013) Objective biomarkers of balance and gait
for Parkinson’s disease using body worn sensors. Mov Dis-
ord, 28,1544-1551.
[28] Morris ME, Huxham F, McGinley J, Dodd K, & Iansek
R (2001) The biomechanics and motor control of gait in
Parkinson disease. Clin Biomech, 16, 459-470.
[29] Mak MKY, & Hui-Chan CWY (2002) Switching of move-
ment direction is central to Parkinsonian bradykinesia in
sit-to-stand. Mov Disord, 17, 1188-1195.
[30] Van Uem JMT, Walgaard S, Ainsworth E, Hasmann SE,
Heger T, Nussbaum S, Hobert MA, Micó-Amigo EM, Van
Lummel RC, Berg D, & Maetzler W (2016) Quantitative
timed-up-and-go parameters in relation to cognitive param-
eters and health- related quality of life in mild-to-moderate
Parkinson’s disease. PLoS One, 11, 1-15.
[31] Zijlstra A, Mancini M, Lindemann U, Chiari L, & Zijlstra
W (2012) Sit-stand and stand-sit transitions in older adults
and patients with Parkinson’s disease: Event detection based
on motion sensors versus force plates. J Neuroeng Rehabil,
9, 75.
[32] Louter M, van Sloun RJG, Pevernagie DAA, Arends JBAM,
Cluitmans PJ, Bloem BR, & Overeem S (2013) Subjectively
impaired bed mobility in Parkinson disease affects sleep
efficiency. Sleep Med, 14, 668-674.
[33] Koerts J, König M, Tucha L, & Tucha O (2016) Working
capacity of patients with Parkinson’s disease – A systematic
review. Parkinsonism Relat Disord, 27, 9-24.
[34] Wilcox SK (2010) Extending palliative care to patients with
Parkinson’s disease. Br J Hosp Med (London, Engl 2005),
71, 26-30.
[35] Poewe W (2006) The natural history of Parkinson’s disease.
J Neurol, 253, 2-6.
[36] Del Din S, Godfrey A, Mazzá C, Lord S, & Rochester
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